Sorbonne Venture

Polygon Therapeutics

Polygon Therapeutics is a pioneering French startup in cardioimmunology that aims to develop an innovative biomedicine to improve the acute management of myocardial infarction.

Polygon Therapeutics has developed a monoclonal antibody that targets the immune system to prevent heart damage in ischemic cardiovascular disease. The startup aims to significantly improve outcomes in myocardial infarction and cardiovascular disease.

Activité
Research and development of a biomedicine, improvement of patient prognosis

Secteur
Biotech, Santé

Métier
Venture Deeptech

Statut
In portfolio

Date d'acquisition
2024

Montant de l'investissement
400K